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Background: Trichoderma reesei is known as a good producer of industrial proteins but has hitherto been less
successful in the production of therapeutic proteins. In order to elucidate the bottlenecks of heterologous protein
production, human α-galactosidase A (GLA) was chosen as a model therapeutic protein. Fusion partners were
designed to compare the effects of secretion using a cellobiohydrolase I (CBHI) carrier and intracellular production
using a gamma zein peptide from maize (ZERA) which accumulates inside the endoplasmic reticulum (ER). The two
strategies were compared on the basis of expression levels, purification performance, enzymatic activity, bioreactor
cultivations, and transcriptional profiling.
Results: Constructs were cloned into the cbh1 locus of the T. reesei strain Rut-C30. The secretion and intracellular
strains produced 20 mg/l and 636 mg/l of GLA respectively. Purifications of secreted product were accomplished using
Step-Tactin affinity columns and for intracellular product, a method was developed for gravity-based density separation
and protein body solubilisation. The secreted protein had similar specific activity to that of the commercially available
mammalian form. The intracellular version had 5-10-fold lower activity due to the enzymes incompatibility with alkaline
pH. The secretion strain achieved 10% lower total biomass than either the parental or the intracellular strain. The
patterns of gene induction for intracellular and parental strains were similar, whereas the secretion strain had a broader
spectrum of gene expression level changes. Identification of the genes involved indicated strong secretion stress in the
secretion strain and to a lesser extent also in intracellular production. Genes involved in the unfolded protein response
(UPR) and ER-associated degradation were induced by GLA production, including; hac1, pdi1, prp1, cnx1, der1, and
bap31.
Conclusions: Active human α-galactosidase could most effectively be produced intracellularly in Trichoderma reesei
at >0.5 g/l by avoidance of the extracellular environment, although purification was challenging due to specific activity
losses. Strain analysis revealed that in addition to the issues with secreted proteases, the processes of secretion stress
including UPR and ER degradation remain as bottlenecks for heterologous protein production. Genetic engineering to
eliminate these bottlenecks is the logical path towards establishing a strain capable of producing sensitive heterologous
proteins.
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Trichoderma reesei is a filamentous fungus known pri-
marily for its use as a large scale producer of industrial
proteins [1]. It is established within industry particularly
for its ability to secrete high yields of active enzymes.
This potential is an attractive benchmark to follow when
considering the production of more sensitive heterol-
ogous proteins of significant value and therapeutic appli-
cation, particularly in light of its compatible basis for
humanised glycosylation engineering [2] and GRAS sta-
tus of T. reesei. A limited number of mammalian pro-
teins have been produced successfully in this system,
including bovine chymosin [3] and antibody Fab frag-
ments [4]. One salient feature of the host is its aggres-
sive and opportunistic nature regarding nutrition uptake
[5], with a broad use of complex carbon sources. Such
opportunism often causes issues with the stability of
heterologous proteins [6]; whereby the harsh extracellu-
lar proteolytic environment [7] directly degrades the
sensitive recombinant products. Comparison with other
potential systems for microbial production of high value
proteins demonstrates not only the potential but also
some clear limitations of T. reesei [8]. Optimisation of
the production strategy is therefore one avenue that may
be explored to bypass and also to define these limita-
tions, leading to improved yields of high-value target
proteins.
The most commonly used technique to enhance heter-
ologous protein production in T. reesei is by fusion of the
target protein with a secretion carrier, generally the cata-
lytic domain and linker of the major cellulase enzyme
cellobiohydrolase I. Carrier fusions of this type have
been proposed to have a diversely positive effect on pro-
duction levels by stabilising mRNA, improving intracel-
lular trafficking in the secretory pathway, and proximity
shielding against proteolysis [9]. An alternative strategy
can be to direct intracellular accumulation of a target
protein, previously highlighted by the hydrophobin fu-
sion strategy leading to protein body (PB) formation
[10,11]. Another self-assembling protein that can pro-
mote intracellular accumulation and PB formation is de-
rived from the maize gamma zein storage protein [12],
ZERA®. This fusion technique relies on ZERA’s natural
ability to accumulate in the ER and on ZERA-ZERA in-
teractions driven by intermolecular disulphide bonds,
recruiting the individual fusion proteins into PB struc-
tures. Protein body fusions of this nature have a tight
conformation and are surrounded by the ER membrane,
thereby insulating the foreign protein from other cell
components and avoiding proteolysis to some extent
during cell disruption and PB harvesting.
Human alpha galactosidase A (GLA) was chosen as a
high value model protein for this study on the basis of
its current use in the treatment of Fabry disease [13] byenzyme replacement therapy. GLA is currently produced
commercially in Chinese Hamster Ovary (CHO) cells [14].
Fabry disease itself is an X-chromosome-linked lysosomal
storage disease caused by loss of native GLA activity in af-
fected individuals, allowing a toxic build-up of the sub-
strate globotriaosylceramide. GLA in its mature form is a
46 kDa glycoprotein with four N-glycosylation sites and
five disulphide bridges, and it is active as a 102 kDa homo-
dimer. Enzymatic activity is thought to be independent of
the glycosylation pattern, which is more likely to be im-
portant for structural integrity, solubility, targeting, and
antigenic compatibility [15].
The aim of this study was primarily to investigate
whether authentic and functional GLA can be produced
in T. reesei, and to compare intra- and extracellular pro-
duction strategies in an attempt to reach industrially sig-
nificant production levels of active enzyme. A secondary
aim following this comparison was to reveal the physio-
logical consequences of the two production strategies.
Transcriptional profiling and other techniques were used
to elucidate the cellular mechanisms causing bottlenecks
in production. Equivalence of a fungal version of human
GLA in terms of yield and enzyme functionality would
be a clear indication of the potential of T. reesei as an
economically valid microbial system for the production
of human therapeutic proteins.
Methods
Cloning and strain construction
Constructs for intracellular GLA production were made
from a synthetic gene coding for ZERA-GLA [12], ob-
tained from Geneart (Regensburg, Germany). GLA [NCBI
Gene ID: 2717] was optimised to the T. reesei genomic
codon bias and 40 bp homologous overlaps with the des-
tination vector pHH01 [16] were included to excise a PacI
site upstream and downstream respectively; CATCTTTT
GAGGCACAGAAACCCAATAGTCAACCGCGGAC,
GACCTACCCAGTCTCACTACGGCCAGTGCGGCGGT
ATTGG. pHH01 is aT. reesei expression vector with a yeast
backbone and sequences for amplification in E. coli, also
containing an acetamidase selection marker, and a cbh1
promoter and terminator with 3′ integration flanks to the
cbh1 locus in T. reesei (Figure 1). The secreted GLA con-
struct was made by nested PCR cloning using Phusion HF
polymerase (Thermo Fisher Scientific Inc. Waltham, MA,
United States of America) according to the manufacturer’s
two step protocol conditions with a cbh1 DNA template
and the synthetic GLA plasmid. A forward oligo was used,
overlapping pHH01 followed by a cbh1 priming region
(CATCTTTTGAGGCACAGAAACCCAATAGTCAACC
GCGGACATCATGTATCGGAAGTTGGCCGTCATCTC
GG) with a reverse oligo designed to introduce a KEX2
protease site between the native CBHI carrier and recom-
binant GLA (GCGCTGGCGGTGTAGGTGGTGCGCT
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Figure 1 Map of DNA constructs. (A) The construct was designed to secrete the target protein human GLA (hGLA) under the cbh1 promoter
(pcbh1) with the aid of a CBHI secretion signal (ss) and CBHI carrier fusion (cbh1), which was to be proteolytically cleaved at a KEX2 site (KEX) on
route to secretion. A TEV protease site (TEV) was also included for downstream polishing after purification by Strep Tactin affinity using a strep2
tag (strep2) (B) Three variations of GLA were designed with RGD integrin (RGD) targeting for intracellular accumulation by ER retention of the
Zera® peptide system (ZERA). The cbh1 locus was used as an integration site for all the constructs by homologous recombination using the cbh1
promoter sequence and a section of DNA downstream of the cbh1 region (cbh1 3′). The native terminator sequence (tcbh1) was followed by an
Aspergillus nidulans AmdS (AmdS) marker gene for selective growth on acetamide. The size of the protein expressing region of the secretion
construct was 2775 bp and 1632 bp for both RGD containing intracellular constructs whereas the control construct lacking RGD was 1563 bp.
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After three polymerase chain reaction cycles an add-
itional reverse oligo was added to the mix containing a
GLA priming region with an extra terminal sequence to




ther 30 cycles were performed in order to anneal the en-
tire nested product which contained 20 bp overlaps for
each piece. Yeast homologous recombination cloning
was used for all of the constructs. The expression vector
pHH01 was linearised with a PacI (New England Biolabs
Inc. Ipswich, MA, USA) restriction enzyme between the
cbh1 promoter and terminator and transformed into S.
cervisiae together with the ZERA-GLA and CBHI-GLA
cloning fragments designed to replace the PacI site and
recircularise the plasmid. The transformation mixes were
plated on SCD-Ura [17] for URA3 strain selection and
the recombinant yeast plasmid DNA was then isolated
and transformed to the E. coli DH5 alpha. Positive clones
were identified by restriction enzyme digestions and
DNA sequencing. The T. reesei expression cassettes
shown in Figure 1 were excised from the cloning vectors
using dual PmeI sites (Thermo) and transformed into T.
reesei. Transformations were made using the Rut-C30
strain including a mus 53Δ [18] mutation to enhance
genome-targeted integration according to the standard
protoplast-based protocol [19]. Genomic Integration into
the cbh1 locus was confirmed by PCR screening from
transformants successfully growing on Trichoderma
Minimal Medium (TrMM) acetamide selection plates
[19] after two successive streaks made on selective
medium. Uninuclear clones were obtained by plating sin-
gle colonies from spore suspensions onto selection plates
and finally amplified for spore culturing stocks on potato
dextrose DIFCO 213400 agar plates (Becton, Dickinson
and Co. New Jersey, USA).Culturing
Small scale 300 ml cultivations were performed in two
litre shake flasks with TrMM buffered to pH 4.8 with
100 mM piperazine-n, n’-bis 3-propanesulfonic acid, and
supplemented with 4% lactose Fagron 208090–0002
(Fagron Nordic A/S. Copenhagen, Denmark), 2% soluble
spent grain (extracted from solid grain material (Harbro
Ltd. Turriff, Aberdeenshire, United Kingdom) at pH 5.0
by adjustment with NaOH and using a 115°C heating
step for 10 mins before centrifugation to obtain the sol-
uble fraction), and 0.2% peptone. Five separate transfor-
mants were grown for each construct and compared for
growth and expression levels in order to establish a rep-
resentative clone for upscale culturing. Protease inhib-
ition cultivations for the CBHI-GLA secretion strain
were performed in Whatman™7701-5102 24 well culture
plates (GE Healthcare UK Ltd. Little Chalfont, Bucking-
hamshire, United Kingdom) with the same medium in
4 ml volume including daily dosing of 10 nM pepstain A
SIGMA P5318 (Sigma-Aldrich Co. LLC. St. Louis, MO,
United States of America), 10 nM chymostatin SIGMA
C7268, 5 mM EDTA, and 0.2 mg/ml trypsin inhibitor
SIGMA T9128.
Larger scale bioreactor cultivations were performed in
order to obtain sufficient material for purification of com-
parable test batches. 20 litre cultivations in a Braun Biostat
C-DCU3 bioreactor (Sartorius AG. Göttingen, Germany)
were started with a 10% inoculum, grown on 40 g/l lactose
with 33% (v/v) of a soluble extract of spent grain. The bio-
reactor medium contained 60 g/l lactose with 40% (v/v) of
the same spent grain extract. Cultivation conditions were
controlled as follows; pH was maintained at 4.5 ± 0.5 using
NH4OH, foaming was controlled by automatic addition of
Dow Corning 1500 antifoam agent when required (Dow
Corning Corp. Midland, Michigan, United States of
America), dissolved oxygen was maintained above 30% by
agitation (400–550 rpm) and oxygen enrichment of the gas
flow (0-66%) at a constant gas flow rate of 8 l/min, and
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with lactose feeding (200 g/l) starting at the end of the
batch phase was controlled by an algorithm based on the
consumption of base for pH control [20,21].
Bioreactor cultivations for transcriptional profiling
were performed in triplicate from a single inoculum per
strain in one litre Sartorius Q DCU4 bioreactors using
4% lactose and 2% spent grain extract; all other parame-
ters were controlled as in the previous batch method.
Protein gels and Western blot analysis
SDS PAGE samples were made with LI-COR 928–40004
protein sample loading buffer (LI-COR Biosciences Inc.
Lincoln, NE, United States of America), a pre-cast
Biorad Criterion gel system (Bio-Rad Laboratories Inc.
Hercules, CA, United States of America) and blotted by
a semi dry Biorad Transblot Turbo Western blotting
system. Blots were then probed with primary antibody
(anti ZERA rabbit αR8 1:7000 [12], Santacruz anti GLA
H104 rabbit 25823 1:1000 (Santa Cruz Biotechnology
Inc. Dallas, Texas, United States of America), iBA Strep-
MAB classic 21507001 1:2000 (IBA GmbH. Göttingen,
Germany), anti CBHI MAB261 1:1000 [22]) and quanti-
fied using a fluorescent secondary antibody: ODYSSEY IR
Dye 680RD 92668071 1:10000/IRDye 800CW 92632710
1:10000 (LI-COR) and a LI-COR ODYSSEY CLX system
for near infrared scanning and quantification). Quantifica-
tions were based on a moving average curve fit from five
different dilutions of a protein standard. A representative
batch of ZERA-GLA was chosen as a positive control and
quantification standard by first quantifying against a com-
mercial GLA from E. coli 12078-H08H (Sino Biological
Inc. Beijing, China) using GelCode Blue G250 Coomassie
stain (Thermo). Duplicate protein samples were used for
each quantification. The densitometry calculations were
processed with ImageQuant TL software (GE Healthcare)
based on a best fit curve of five GLA standard dilutions.
CBHI carrier quantities within the culture sample were
determined against a pre-quantified batch of CBHI control
protein (VTT Technical Research Centre of Finland,
Espoo, Finland).
Purification of GLA
Mycelial biomass from ten litres of fermentation broth was
harvested by vacuum filtration on double-layered 240 mm
diameter Whatman GF/A filter paper (GE Healthcare) in a
Büchner apparatus and washed with reverse osmosis water
before being frozen at −20°C for storage. Many different
buffer conditions and methods for cell breakage, PB extrac-
tion and solubilisation were tested both for protein and en-
zyme activity yield, as briefly outlined in Figure 2, before a
standard protocol was determined. In this protocol 1 g of
the cell material was resuspended in 10 ml of 10% sucrose,
10 mM NaH2PO4 ( pH6.5), 1% Triton x100, 2 mM EDTA,1 mM Phenylmethanesulfonyl fluoride Sigma P7626 and
10 μM Pepstatin A and homogenised by a 10 mm Polytron
PT1200 disrupter probe (Kinematica AG. Luzern,
Switzerland). The homogenous material was then sub-
jected to three passes through an SLM Aminco FA030
French press (Horbia Instruments Inc. Irvine, CA,
United States of America) at 20,000 psi. Initial separ-
ation of PBs from leftover biomass was performed in
50 ml tubes by centrifugation for 5 minutes at 200 × g.
After separation from the mycelial pellet, the super-
natant containing soluble cell extracts, small aggre-
gates and the protein bodies was then used to enrich
the protein bodies by centrifugation at 2000 × g for
10 minutes. Two washes were then performed on the
pellet material using 10 mM NaH2PO4 (pH6.5) and 1%
Triton-X100, to remove any endoplasmic reticulum
membranes. PB-enriched aliquots were then made
from one millilitre of original material and frozen for
solubilisation method development.
The solubilisations were based on a controlled concen-
tration ratio from disrupted biomass, e.g. 1 g of mycelial
fresh weight was disrupted in 10 ml of breakage buffer,
and PBs were then enriched into a small pellet and
reconstituted in 1 ml of solubilisation buffer to a maximum
concentration of approximately 2.5 mg/ml ZERA-GLA. A
buffer containing 50 mM Bicine pH 8.2, 5% Gly-
cerol, 150 mM NaCl, 16 mM Sarkosyl, 10 mM β-
mercaptoethanol was used to resuspend the PB pellet
before treatment in a Fritsch Laborette 17.202 sonic
bath (Fritsch GmbH. Idar-Oberstein, Germany) for one
minute. The suspended PB pellets were left to solubilise
overnight at +8°C on a Brunswick TC7 roller drum
(Eppendorff AG. Hamburg, Germany). The soluble
fraction was recovered by centrifugation at 20,000 × g
for 30 minutes. Proteolytic cleavage of the GLA enzyme
from ZERA was achieved by use of a monomeric TEV
protease Invitrogen AcTEV 12575 according to the
manufacturer’s instructions (Thermo).
Secreted GLA was purified using an IBA 2-1531-001
Strep-Tactin 1 ml flow column by adjustment of the sam-
ple pH to 7.5 using NaOH and elution by acid-driven dis-
association in 50 mM sodium acetate activity buffer,
pH 4.5 according to the manufacturer’s instructions.
GLA activity assay
Activity measurements were made by mixing a 25 μl
enzyme sample into 100 μl of the 2.46 mM fluorescing
substrate 4-methyl-umbelliferyl-alpha-D-galactopyrano-
side Sigma M7633 in 10 mM acetic acid, pH 4.5. The
enzyme reactions were continued for one hour on an
orbital shaker at 37°C before being stopped by addition
of 1.25 ml 200 mM glycine solution at pH 10.4. A
standard curve was prepared of 0–500 ng/ml of 4-
methylunbelliferone Sigma M1381. All samples were
Figure 2 Schematic workflow of the protein purification protocol development. Biomass for the intracellular production strains was extracted
by various PB harvesting techniques and eventually solubilised under many different conditions requiring stepwise optimisation. The effects at each
step were measured by Western blotting for yield increase and by activity assay, to determine whether integrity of the GLA enzyme fusion was
retained. The harvesting, PB treatment and solubilisation methods tested are shown in the arrows, and the final solubilisation conditions are shown in
the circle on the top. A plus sign (+) represents an increase in active yield and two or three such signs show the approximate magnitude of this effect.
Similarly one to three negative signs (−) denote the magnitude of active yield decrease. A null effect sign (Ø) was used where there was no apparent
change in active yield. Some additives have both signs to show that the effect of active yield was dictated by a change in molarity of the additive.
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read at 450 nM on a Varioskan (Thermo). Activity units
were expressed as μmol of 4-methylumbelliferone/h/mg
protein.
RNA isolation and array hybridisation
Mycelial samples from the one litre bioreactors were
collected by vacuum filtration on Whatman GF/A filter
paper and then rinsed in 0.9% NaCl and frozenimmediately in liquid nitrogen. RNA was isolated from
50 mg of the mycelia with RNeasy Plant RNA isolation kit
(Qiagen GmbH. Hilden, Germany). RNA quality was
assessed for purity and quantity using an Agilent RNA
6000 analyser (Agilent Technologies Inc. Santa Clara, CA,
United States of America) The purified RNA was then
converted into cDNA using an Invitrogen Superscript
Double-Stranded cDNA Synthesis Kit (Thermo) prior to
labelling with Cy3 One-Colour fluorescent dye (Roche
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ufacturer’s instructions. The labelled cDNA was hybridised
on an automated HS12 system (Roche) to custom-made
four plex microarray slides (Roche) designed from the T.
reesei genome version 2.0 [23,24]. Analysis was performed
in an MS200 microarray scanner (Roche) to identify signal
probe intensity of the six 50-74mer probe replicates de-
signed from the known and predicted genes in T. reesei.
Microarray data analysis
R/Bioconductor (http://www.r-project.org) was used for all
data analysis. The raw data was normalized with Robust
Multichip Average (RMA) normalization [25]. The quality
of the microarray data was assessed on the basis of a report
from the arrayQualityMetrics–package [26] and by obser-
vation of the distribution of the log2 intensities on each
array before and after normalization (Additional file 1A).
Additionally, the similarity of replicate samples to each
other was verified by plotting the arrays on a two di-
mensional display using principal component analysis
(Additional file 1B).
Statistical differences in expression were analysed
using linear modelling with tools of the limma package
[27]. For each gene, a linear model was fitted by the least
squares method and differential expression within pairs
of experimental conditions was computed using an em-
pirical Bayesian approach [28]. Genes with log2-scale
fold change > +\-1 were considered to be up- or down-
regulated, respectively. The significance test results were
visualized as volcano plots showing the expression level
difference (log2-transformed fold change) versus the sig-
nificance of the change (−log10 of the p-value). The vol-
cano plot shows, at a glance, the number of changes
between the strains being compared. In a large and out-
spread volcano plot, genes in the top-left and top-right
corners of the plot are most significantly down- or up-
regulated. A small and shallow volcano indicates that
there were no significant changes between the condi-
tions, i.e. that the changes in the expression levels were
small (below twofold) and insignificant (p-value >0.001).
Results
In order to compare the two different production strat-
egies of human α-galactosidase in T. reesei, four expres-
sion constructs were made from a synthetic gene codon-
optimised to T. reesei codon usage and transformed into
the fungus (Figure 1). In one construct GLA was fused
to the T. reesei cbh1 catalytic domain and linker region
in order to provide a secretion carrier. For the remaining
constructs GLA was fused with ZERA peptide to pro-
mote protein body formation inside the cell. Three of
the constructs had RGD peptides attached at either end
of GLA to enhance its localisation in the lysosome for
its use in enzyme replacement therapy for humans. Thetransformants obtained for each of these constructs were
purified through single spore cultures, and integration of
the expression construct to the cbh1 locus was verified
by PCR analysis.
Production of human α-galactosidase in T. reesei
Five individual transformants for each of the Intracellu-
lar ZERA-GLA variants and CBHI-GLA secretion strain
were grown in replicate shake flask cultures. GLA pro-
duction yields quantified by near infra-red Western blots
were approximately 90 mg/l for all the intracellular
ZERA-GLA variants, whereas the secreted CBHI-GLA
product was barely above the limit of detection. No
growth defects were observed and there was no signifi-
cant variation in production levels between the repli-
cates, and therefore one representative clone for each
strain was chosen for up-scaled production. Secreted
CBHI-GLA was deemed unsuitable for bioreactor stud-
ies due to its instability and low GLA yield. However, its
production level was eventually improved to around
20 mg/l in 24-well plate cultures and to a total of 60 mg/l
including CBHI carrier bound forms by addition of a cock-
tail of protease inhibitors (Figure 3A). The strain expressing
ZERA-GLA with C-terminally attached RGD peptide was
grown in a 20 litre batch cultivation and ZERA-GLA lack-
ing RGD peptide was produced in a 20 litre fed batch culti-
vation based on the monitoring observations of the
previous batch run.
Batch cultivation for ZERA-GLA produced 267 ±
18 mg/l and the subsequent fed-batch bioreactor run with
extended lactose feeding increased the yield to 636 ±
41 mg/l. When including proteolytic cleavage products in
the quantification, the total detected amount found in the
cells was around 1200 mg/L (Figures 3B and C). In both
the batch and fed-batch cultivations growth was similar to
that of the parental strain and peak expression of ZERA-
GLA was achieved at the end of the cultivations when
CO2 levels had decreased almost to the baseline after ex-
haustion of carbon source.
Purification and enzyme activity measurements of human
GLA
In the ZERA peptide protein body purification concept
the target protein is purified from lysed cell material
based on the high density of the PBs. Developing a
protocol for GLA isolation and solubilisation required
extensive trials and optimisation (Figure 2), but ultim-
ately a relatively robust protocol was established. In our
initial purification trials we focused on optimising recov-
ery of PB material from the mycelia. In the case of mild
disruption methods such as the use of homogenisation
blenders, PBs could not be extracted efficiently. In more
harsh disruption methods such as grinding and bead






















































































































Figure 3 SDS-PAGE and Western blot analysis of the proteins produced. (A) Secreted CBHI-GLA purified via strep2 affinity, measured by
strep-tactin-AP Western blot (100 ng loaded). The 50 kD band represents the GLA cleaved by KEX2 protease from the CBHI carrier. The larger band remains
as a CBHI-GLA fusion. (B) Comparison of a solubilised batch of purified ZERA-GLA (Z-GLA pure) compared to commercial GLA (GLA control) (1 μg of each).
The ZERA-GLA protein runs about 10 kD higher than commercial GLA as expected. (C) The same ZERA-GLA batch compared to ZERA-GLA contained in
mycelium (Z-GLA Biomass) and extracted directly from filtered mycelia by boiling in protein sample loading buffer (1 μl of each). Detection by anti ZERA
Western blot reveals the presence of several lower molecular weight degradation products contained within the cell, still retaining the ZERA peptide. (D) A
TEV protease cleavage of GLA from the ZERA peptide (TEV digest) directly using a 10-fold digest buffer dilution of insoluble enriched protein body material
(Z-GLA PB), compared to 0.5 μg of commercial GLA and 1 μg of the purified soluble form of ZERA-GLA. 5 μl were loaded for both the digest and starting
PB material. The anti GLA Western blot shows that while cleavage is possible from insoluble PBs three lower molecular weight forms of GLA are present,
perhaps due to endogenous protease. (E) A four step pellet wash purification of the ZERA-GLA PB material from a 5 μl sample of 1 g fresh weight diluted
in 10 ml (PB) showing the soluble components removed from the PB material with a 5 μl sample of tenfold concentration increase (Wash). The PB pellet is
then solubilised in the same volume and centrifuged leaving insoluble debris (Pellet) and the soluble ZERA-GLA (Solubilisation) (5 μl for both).
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in a French press with added Triton detergent allowed for
sufficient disruption of the mycelial biomass without
harming the PBs, which could subsequently be harvested
efficiently by differential gravity separation. The remaining





























Figure 4 Enzyme activity in relation to recovered yield from insoluble
a neutral to alkaline pH range and tested for target protein concentration by
specific activity loss trade-off vs. concentration yield, by solubilisation pH channumber of additives and detergents in a range of different
buffers (Figure 2). These were then individually assessed
for solubilisation yield and GLA activity and the best con-
ditions were combined and optimised. During this method
development phase for PB solubilisation it became appar-
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material. A pre-pellet washed batch of PB material was solubilised over
quantitative Coomassie stain and GLA enzyme activity measurement. A























Figure 5 Bioreactor data. Batch bioreactor cultivations in triplicate.
The three production strains were cultured in triplicate for the parental
strain (Parental), intracellular production strain (ZERA-GLA) and secretion
strain (CBHI-GLA) and then analysed by transcriptional profiling for
physiological observations. (A) Cell dry weight determined over time in
grams of dried biomass per litre of culture volume. (B) Carbon dioxide
monitoring was determined over time and measured in percent
dissolved CO2.
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could be made in 50 mM Bicine buffer, pH 9.5, with the
addition of 50 mM ionic surfactants, either SDS or Sarko-
syl , 900 mM NaCl and 50 mM BME for reduction of the
ZERA intramolecular disulphide bridges. This led to a
clear protein enrichment of ZERA-GLA from cell lysate
material (Figures 3D and E) with greater than 60% total
recovery of material and >70% purity as determined by
Coomassie staining. Unfortunately these conditions led
to a major reduction of enzyme activity, with eventual
total loss after one freeze thaw cycle. Optimisation of
the pH and molarities of the solubilisation buffer com-
ponents led to retention of a small proportion of the
enzyme activity by trade-off with solubilisation yield
(Figure 4). After optimisation, product concentrations
of 0.1-0.2 mg/ml were observed with a 5-10-fold lower
specific activity than the commercially available CHO-
derived enzyme. Proteolytic release of GLA enzyme
from the ZERA fusion could then be achieved at the
TEV cleavage site using a monomeric TEV protease(Figure 3D); the specific activity after this polishing
procedure remained unchanged.
The specific activity of CBHI carrier-secreted GLA
collected by Strep tag purification was comparable to
that of the commercial enzyme Replagal (results not
shown). However, this method of production and purifi-
cation was unreliable due to high levels of product deg-
radation and loss. Secreted GLA became unstable during
the Step-Tactin binding process when the acidic culture
pH was increased to the neutral pH range of Strep-
Tactin binding conditions, despite the addition of prote-
ase inhibitors.
Physiological consequences of the production strategies
In order to establish the specific physiological and tran-
scriptional changes as a result of either secreted or intracel-
lular production, bioreactor cultivations were performed in
triplicate for each of the parental, GLA-secreting and intra-
cellular production strains. Quantification of cell dry
weights and CO2 formation from the cultivations revealed
that growth of the GLA-secreting strain peaked about
15 hours earlier than both the parental and intracellular
ZERA-GLA strains (Figure 5). The secretion strain also
produced about 10% lower peak biomass. However, ac-
cording to both dry weight and CO2 measurements the
maximal growth rates of the three strains were rather
similar.
The accumulation of intracellular ZERA-GLA was
measured for all replicates (Figure 6). The best producer
was the intracellular ZERA-GLA strain, at 150 mg/l.
These production levels were compared over time, re-
vealing an unexpected pattern of accumulation with two
separate production peaks. ZERA-GLA came to an ini-
tial production peak at around 100 mg/L at 24 hours be-
fore decreasing to ca. 50 mg/L at 35–40 hours and
finally recovering to 150 mg/L after 48 hours. Analysis
of the secretion strain showed that despite the instability
of GLA in culture medium, much higher quantities of
the CBHI carrier fusion partner were accumulated.
Levels of proteolytically cleaved CBHI carrier around
1.3 g/l were observed, precisely tenfold lower than the
13 g/l of endogenous CBHI that was produced in the
parental strain (data not shown).
Transcriptional profiles for parental, secretion and
intracellular production strains were determined by
quantitative comparison of mRNA levels measured by
microarray. The production strategies were compared at
22 hours during the mid-logarithmic growth phase and
after 27 hours at the late-logarithmic growth phase of
cultivation. To identify differentially expressed genes, we
performed significance tests comparing two strains at a
time. The significance test results were visualized as vol-
cano plots showing the expression level difference be-


































































Figure 6 Total yield of target protein production during the bioreactor cultivations. (A) Triplicate cultivations of ZERA-GLA intracellular
production showing total ZERA-GLA expressed over time by quantification from anti-ZERA Western blot analysis. Two peaks of ZERA-GLA production
are apparent, separated by a decline in the ZERA-GLA level at approximately 30 to 45 hours of the culture. (B) A comparison of CBHI carrier produced as
a result of CBHI-GLA production by secretion vs. intracellular ZERA-GLA production over time. By assessing the more stable CBHI carrier by quantitative
anti CBHI Western instead of the unstable secreted GLA product it is clear to note that despite the eventual loss of secreted GLA through proteolysis
more total GLA was actually produced than with the intracellular ZERA-GLA (quantified by anti ZERA Western).
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These volcano plots (Figure 7A) showed that in the se-
cretion strategy the mRNA transcript levels of many
genes had changed compared to the parental strain, in
most cases by an increase in gene transcription. The
gene expression during the intracellular production
strategy is relatively similar to that of the parental strain,
the only significant shift in data spread being at 22 hours
when a small number of up-regulated genes were over
twofold induced. In general the transcriptional changes
observed followed a similar pattern when progressing to
the 27 hour time point, albeit at a reduced level of fold
change. Further analysis of the secretion vs. intracellular
strain at these relevant time points, and comparison of
the genes with significant changes, demonstrated that
similar changes had occurred for both forms of produc-
tion, although the relative level of fold change in regula-
tion was lower for the intracellular production and often
did not exceed the twofold change threshold. The listing
of genes up-regulated during GLA production by category
shows that genes involved primarily in metabolism, trans-
port, and translation were enriched (Figure 7B).
Genes related to the secretion pathway are obviously of
special interest. A number of genes involved in UPR and
protein folding or degradation in the ER (ERAD) are in-
duced (Additional file 2). These induced genes include
hac1, encoding a transcription factor of UPR, the protein
disulphide isomerase pdi1, PDI-related prp1, the chaperone
calnexin cnx1, and the ERAD pathway genes der1 and
bap31. This observation suggests that both the secretion
strain and the intracellular strain suffer from secretion
stress. As the extent of induction of these genes is higher in
the secretion strain, it appears that this strain suffers more
strongly from secretion stress than the intracellularproduction strain. This can be shown specifically by analys-
ing the differences in gene induction; for example hac1 and
der1 are above the twofold change threshold in the secre-
tion strain at 2.23 and 2.02, but below the threshold in the
intracellular strain at 1.45- and 1.73-fold.Discussion
Human GLA was produced in T.reesei to >0.5 g/l levels
with the aid of the ZERA fusion partner. However, sev-
eral noteworthy limitations of this production strategy
were revealed. Attempts to produce this enzyme by the
classical CBHI carrier secretion method were initially
unsuccessful. It was possible to obtain low mg/l yields
by addition of a strong cocktail of protease inhibitors to
the culture media and harvesting at an early time-point
before significant proteolytic degradation occurred (data
not shown). The fact that far higher quantities of CBHI
carrier lacking the GLA fusion partner were observed
from these cultures, coupled with the knowledge that
CBHI fusion carriers have previously been successfully
used for more proteolytically stable proteins such as Fab
fragments [4], demonstrates the influence of the extra-
cellular protease profile of T.reesei in the degradation of
sensitive heterologous proteins. Traditionally it has been
challenging to produce large quantities of mammalian
proteins in filamentous fungi [8], and this was the driv-
ing force to investigate the possibilities of intracellular
protein production using the ZERA PB storage system.
It was therefore not surprising to note the relative suc-
cess of intracellularly accumulated GLA, providing fur-
ther evidence that it is indeed possible to express
functional mammalian therapeutic proteins in T. reesei








































































































































Mutual S vs. P 
& I vs. P
Metabolism 28 23 7 3
Mitochondrial 8 8 3 3
Glycoside Hydrolase 6 5 1 0
Carbohydrate 
Metabolism 2 2 1 1
Amino Acid 
Metabolism 3 2 1 0
Motility/Cell wall 5 4 2 1
Transport 10 8 1 0
Signalling 2 2 0 0
Regulatory 7 7 0 0
Nucleosome/DNA 4 4 2 2
Transcription/RNA 6 6 0 0
Translation 26 25 11 10
Secretory Pathway 7 6 3 2
Folding/UPR 6 5 3 2
Degradation/ERAD 4 3 3 2
Vacuolar 2 2 1 1
Secreted 6 4 4 3
Unknown 20 19 4 3
Total 152 135 47 33
Figure 7 Transcriptional profiling data comparing the production strategies. (A) Volcano plots of the combined triplicate RNA microarray
data at the points of highest interest, 22 and 27 hours showing the spread of gene expression events in terms of up and down regulation
between each production strategy comparison. (B) A table showing the transcriptional changes exceeding the 2-fold change threshold for each
comparison and also listed by gene category throughout the cultivations. The total number of hits shows the combined number of transcriptional
changes for all of the production strategies and the final column shows the mutual transcriptional changes observed between secretion
and intracellular production. In the case of intracellular production most of these transcriptional changes observed are also found in the mutual
category showing that many similar genes are highlighted between both types of production.
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tive success of obtaining full length GLA from intracellu-
lar accumulation, there is still an intrinsic difference
between secretion ability and cell storage capacity in
T. reesei. Quantification of CBHI carrier levels observed
from the bioreactor cultures revealed a near tenfold higher
production level of CBHI carrier cleaved from secreted
GLA than intracellular ZERA-GLA; 1300 mg/l and
150 mg/l, respectively. This shows that despite the low yield
of actual GLA observed due to proteolysis, more GLA was
in fact synthesized in the strain producing secreted GLA as
compared with the strain producing intracellular ZERA-
GLA. Furthermore, the levels of endogenous CBHI from
the parental strain were a further tenfold higher at around
13 g/l (data not shown). Clearly there are not only issues
with stability of GLA during secretion or after secretion
but also common cellular mechanisms capable of limiting
the basal expression or retention of this human enzyme.When considering the quality of recombinant GLA
enzyme, the primary concern is its ability to be purified
while retaining relevant levels of specific activity. Despite
the low yields of full size GLA obtained by carrier secre-
tion a small quantity was purified, with specific activity
close to that of the commercial form obtained from
CHO. This was not an unexpected result considering
that T. reesei is a known producer of high quality recom-
binant enzymes; however it was significantly more chal-
lenging to reproduce similar levels of specific activity
from ZERA-GLA produced intracellularly. Establishing a
purification method for intracellular ZERA-GLA re-
quired greater focus, having not been previously tested
in any filamentous fungi. Extraction of intact PBs from
the mycelial biomass required rather harsh yet well-
defined disruptive forces so as not to also disrupt the PBs.
Once the PBs were obtained, the methodology to enrich
and wash to some extent by gravity-based separation was
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more comparable way, solubilisation of the PBs would be
required. As the results observed above demonstrate, it
was possible to solubilise ZERA-GLA under several condi-
tions but loss of specific activity occurred to some extent
in every case. The most important criteria for solubilisa-
tion of the ZERA-GLA fusion were high pH with the
addition of a reducing agent and ionic surfactants. Unfor-
tunately, these factors resulted in significant loss of en-
zymatic activity. It was possible by adjustment of the
molarity of the solubilisation buffer components, com-
bined with optimisation of pH, to retain some of the activ-
ity, although at the cost of lower solubilisation yield. A
specific activity to yield trade-off was established at around
pH 8.2 although at this pH only 10-20% of the PB material
was recovered, compared with almost 100% using highly
basic pH. Cleavage of GLA from the ZERA fusion by TEV
protease could be achieved, but enzymatic activity did not
recover. These findings are probably due to the natural en-
vironment of GLA contained within the lysosome. With
its low pH optimum of 4.5, the enzyme is likely to be in-
nately less stable and less suitable for purification in basic
conditions. In the comparison of these two production
strategies it is relevant to note that both methods have cer-
tain advantages and also challenges. Moreover, selection of
more compatible model proteins without such stringent
requirements could lead to more encouraging results.
Despite the various challenges of both secreted and
intracellular modes of production, it remains pertinent to
investigate further the physiological and gene level regula-
tion changes of both, in order to shed light on the cellular
processes and production bottlenecks involved. As a gen-
eral summary it can be concluded that production of GLA
as a secreted product fused with the CBHI carrier caused
a more pronounced stress effect with many more up-
regulated genes, than the intracellular ZERA strategy. This
correlated with the results based on cell growth, which
not only peaked earlier during bioreactor cultivation but
also reached a lower overall total biomass than the paren-
tal culture. By contrast, intracellular production strains
grew in an almost identical manner to the parental con-
trol. Many of the genes up-regulated were identified in
both strains, but the extent of the up-regulation was
higher in the secretion strain. This could mean that in the
secretion strain the foreign protein is detected more
strongly as it travels through the whole secretion pathway.
By contrast the ZERA-GLA protein is probably only
present in high concentrations in the ER before being
packed into protein bodies, and is therefore not detected
with equal strength. It was interesting to observe that the
production levels of ZERA-GLA during fermentation
occurred in two distinct peaks (Figure 6B). An early peak
occurred at the end of the logarithmic growth phase,
dropping to around half during stationary growth, beforerecovering to a final and eventually higher peak at the end
of the stationary phase. The second and highest peak in
production appeared to occur when maximum biomass
had been reached and presumably energy resources for
growth were no longer in competition with target protein
production. This phenomenon of a mid-point drop in
total production yield suggests the existence of mecha-
nisms capable of clearing the heterologous protein out
from the ER. This conclusion is also supported by the fact
that many of the significant transcriptional changes
observed point towards secretion stress. It is also possible
that during secretion stress further feedback controlling
down-regulation of target protein biosynthesis is initiated,
causing additional yield limitations [29].
Conclusions
Enzymatically active human GLA was successfully pro-
duced in T. reesei at detectable levels by CBHI carrier se-
cretion and more significantly to >0.5 gram per litre levels
by intracellular accumulation with the ZERA peptide fusion
strategy. It was possible to partially purify GLA from both
production modes, although loss of specific activity was a
challenging aspect concerning purification of the ZERA fu-
sion product. Transcriptional profiling showed that secre-
tion stress is induced in T. reesei in both of the production
modes, albeit more strongly by the secretion strategy.
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